annb0t
Top 20
Mesoblast Limited
At June 30, 2022, cash-on-hand was US$60.4 million with pro-forma US$105.5 million after raising gross proceeds of US$45 million via a private placement in August, 2022 Up to an additional US$40 million available from existing facilities subject to certain milestones Net operating spend of US$65.8 million for the 12 months ended June 2022, a 35% reduction on comparative year, with continued focus on cost control BLA resubmission for remestemcel-L in children with SR-aGVHD exp...
>>> Read more: Mesoblast Reports Financial Results and Operational Highlights for Fiscal Year Ended June 30, 2022
At June 30, 2022, cash-on-hand was US$60.4 million with pro-forma US$105.5 million after raising gross proceeds of US$45 million via a private placement in August, 2022 Up to an additional US$40 million available from existing facilities subject to certain milestones Net operating spend of US$65.8 million for the 12 months ended June 2022, a 35% reduction on comparative year, with continued focus on cost control BLA resubmission for remestemcel-L in children with SR-aGVHD exp...
>>> Read more: Mesoblast Reports Financial Results and Operational Highlights for Fiscal Year Ended June 30, 2022
